Reading view

mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say

Pharmaceutical partners Moderna and Merck announced on Wednesday that their novel mRNA-based vaccine—individually tailored to target a patient's unique cancer mutations—was effective in a late-stage clinical trial of patients with melanoma, one of the deadliest forms of skin cancer.

The announcement was scant on details, but if the success holds, it stands to realize the high aspirations for both mRNA vaccines and individualized cancer-targeting medicines in cancer therapy, providing a first success for both treatment types.

The Phase 3 trial included 1,137 patients who had stage IIB–IV melanoma that had been surgically removed prior to their treatment in the trial. Patients were randomized 2-1 to receive either a combination treatment of the tailored mRNA vaccine (intismeran or mRNA-4157) with Merck's established monoclonal antibody cancer treatment Keytruda, or they received treatment with Keytruda alone. Both patient groups were treated for about a year. The trial was placebo-controlled and double-blind, meaning neither the doctors nor the patients knew which treatment patients were randomly assigned to receive.

Read full article

Comments

© DeFodi Images

  •  

US wait times for cancer surgeries are getting longer and longer

As cancer treatments have advanced and outcomes have improved, one aspect of cancer care in the US has consistently worsened over the last decade: the wait time for surgery.

According to a study in JAMA Surgery, patients with one of six types of cancer—breast, colon, lung, pancreatic, gastric, and esophageal—have faced longer wait times for surgery than in 2012. Timeliness is considered a core metric of healthcare quality, and delays in cancer surgery have been linked to poorer outcomes, including reduced survival rates and increased patient anxiety and distress.

The findings of the new study are based on data from over 2.7 million patients who had been diagnosed with non-metastatic stage I–III cancers requiring surgery between 2012 and 2023. Researchers led by cancer expert Timothy Donahue at the University of California, Los Angeles, broke that time frame up into four groups: 2012–2015, 2016–2019, 2020–2021, and 2022–2023 to see how wait times have changed over the period.

Read full article

Comments

© Getty | AFP

  •  
❌